Thermo Fisher Scientific Inc. announced that its Board of Directors has authorized the repurchase of $4 billion of shares of its common stock. This new authorization has no expiration date and replaces the company’s existing repurchase authorization, which had approximately $1 billion remaining.
This significant capital deployment strategy underscores the company's confidence in its financial position and its commitment to enhancing shareholder value. Share repurchases can reduce the number of outstanding shares, potentially boosting earnings per share.
The company had previously repurchased $3 billion, or 5.5 million shares, during the first nine months of 2024. This new authorization continues Thermo Fisher's disciplined approach to capital allocation, balancing investments in growth with direct returns to shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.